Management of treatment resistance-Treatment-resistant schizophrenia
© 2024. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature..
Despite a very high prevalence and substantial impairments among affected individuals, treatment-resistant schizophrenia (TRS) has not been sufficiently researched in clinical research in the field of psychiatric disorders and the pathophysiology is still poorly understood. A better clinical and pathophysiological understanding of this heterogeneous and severely affected population of people with persistent symptoms in different domains is necessary in order not only to be able to intervene early but also to develop novel therapeutic strategies or individualized treatment approaches. This review article presents the state of the art criteria of the pharmacological TRS, neurobiological disease models and predictive factors for TRS as well as the phenomenon of pseudo-treatment resistance and the clinical management of TRS. In the future, not only the use of operationalized criteria and definitions of TRS in longitudinal studies and randomized-controlled trials (RCTs) are paramount, but also the observation of trajectories with the integration of multimodal longitudinal phenotyping and the longitudinal collection of clinical routine data in academic research, which will be possible in the newly created German Center for Mental Health (DZPG).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Der Nervenarzt - (2024) vom: 06. Feb. |
| Sprache: |
Deutsch |
|---|
| Weiterer Titel: |
Management von Therapieresistenzen – therapieresistente Schizophrenie |
|---|
| Beteiligte Personen: |
Wagner, Elias [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
English Abstract |
|---|
| Anmerkungen: |
Date Revised 06.02.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1007/s00115-024-01608-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368085856 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368085856 | ||
| 003 | DE-627 | ||
| 005 | 20240206232342.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240206s2024 xx |||||o 00| ||ger c | ||
| 024 | 7 | |a 10.1007/s00115-024-01608-6 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1282.xml |
| 035 | |a (DE-627)NLM368085856 | ||
| 035 | |a (NLM)38319320 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ger | ||
| 100 | 1 | |a Wagner, Elias |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Management of treatment resistance-Treatment-resistant schizophrenia |
| 246 | 3 | 3 | |a Management von Therapieresistenzen – therapieresistente Schizophrenie |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 06.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2024. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature. | ||
| 520 | |a Despite a very high prevalence and substantial impairments among affected individuals, treatment-resistant schizophrenia (TRS) has not been sufficiently researched in clinical research in the field of psychiatric disorders and the pathophysiology is still poorly understood. A better clinical and pathophysiological understanding of this heterogeneous and severely affected population of people with persistent symptoms in different domains is necessary in order not only to be able to intervene early but also to develop novel therapeutic strategies or individualized treatment approaches. This review article presents the state of the art criteria of the pharmacological TRS, neurobiological disease models and predictive factors for TRS as well as the phenomenon of pseudo-treatment resistance and the clinical management of TRS. In the future, not only the use of operationalized criteria and definitions of TRS in longitudinal studies and randomized-controlled trials (RCTs) are paramount, but also the observation of trajectories with the integration of multimodal longitudinal phenotyping and the longitudinal collection of clinical routine data in academic research, which will be possible in the newly created German Center for Mental Health (DZPG) | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Neurobiology | |
| 650 | 4 | |a Phenotyping | |
| 650 | 4 | |a Prevalence | |
| 650 | 4 | |a Pseudo-resistance | |
| 650 | 4 | |a Treatment resistance | |
| 700 | 1 | |a Borgwardt, Stefan |e verfasserin |4 aut | |
| 700 | 1 | |a Hasan, Alkomiet |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Der Nervenarzt |d 1947 |g (2024) vom: 06. Feb. |w (DE-627)NLM000034320 |x 1433-0407 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:06 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00115-024-01608-6 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 06 |c 02 | ||